Janssen COVID-19 Vaccine
Janssen COVID-19 Vaccine is available under EUA as a single primary vaccination dose for individuals 18 years of age and older and as a single booster dose for individuals 18 years of age and older at least two months after completing primary vaccination with the vaccine.
The Janssen COVID-19 Vaccine is also authorized for use as a heterologous (or “mix and match”) single booster dose for individuals 18 years of age and older following completion of primary vaccination with a different available COVID-19 vaccine. For example, Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 vaccine recipients 18 years of age and older may receive a single booster dose of the Janssen COVID-19 Vaccine. View COVID-19 vaccine booster eligibility.
- Emergency Use Authorization Status:
- Authorized
- Name:
- Janssen COVID-19 Vaccine
- Manufacturer:
- Janssen Biotech Inc.,
a Janssen Pharmaceutical Company of Johnson & Johnson
Authorized Use
For the prevention of coronavirus disease 2019 (COVID-19) for individuals 18 years of age and older
Common Side Effects
The most commonly reported side effects were pain at the injection site, headache, fatigue, muscle aches and nausea. Most of these side effects occurred within 1-2 days following vaccination and were mild to moderate in severity and lasted 1-2 days. Learn more.
Fact Sheets (English) and FAQs
| Information | Last Updated |
|---|---|
| Fact Sheet for Healthcare Providers Administering Vaccine | January 11, 2022 |
| Fact Sheet for Recipients and Caregivers | January 11, 2022 |
| Frequently Asked Questions on the Janssen COVID-19 Vaccine | December 13, 2021 |
Regulatory Information
Media Materials and Webcasts
| Information | Date |
|---|---|
| Press Release | October 20, 2021 |
| Media Call | October 20, 2021 |
| Advisory Committee Meeting Webcast | October 15, 2021 |
| Press Release | April 23, 2021 |
| Joint FDA and CDC Press Conference | April 23, 2021 |
| Joint CDC and FDA Statement | April 13, 2021 |
| Joint FDA and CDC Media Call | April 13, 2021 |
| Media Call | February 27, 2021 |
| Press Release | February 27, 2021 |
| Advisory Committee Meeting Webcast | February 26, 2021 |
Translations of the Fact Sheet for Recipients and Caregivers
| 接受者和护理者须知 (November 19, 2021) |
中文 (Chinese, Simplified) |
| 환자와 의료진을 위한 정보지 (November 19, 2021) |
한국어 (Korean) |
|
FEY ENFOMASYON POU MOUN K’AP RESEVWA AVEK MOUN K’AP BAY SWEN (November 19, 2021) |
Kreyòl Ayisyen (Haitian Creole) |
|
DAIM NTAWV QHIA TSEEB RAU COV NEEG TAU KEV PAB THIAB COV NEEG ZOV TU (November 19, 2021) |
Hmoob (Hmong) |
|
បញ្ជីហេតុការណ៍សម្រាប់អ្នកទទួលនិងអ្នកថែរទាំ (November 19, 2021) |
ភាសាអង់គ្លេស (Khmer) |
|
(November 19, 2021) |
Português (Portuguese) |
|
ИНФОРМАЦИОННЫЙ БЮЛЛЕТЕНЬ ДЛЯ РЕЦИПИЕНТОВ И СПЕЦИАЛИСТОВ ПО УХОДУ (November 19, 2021) |
Русский (Russian) |
| HOJA INFORMATIVA PARA RECEPTORES Y PROVEEDORES DE CUIDADO (November 19, 2021) |
Español (Spanish) |
|
|
|
| FACT SHEET PARA SA MGA TATANGGAP AT MGA TAGAPAG-ALAGA (November 19, 2021) |
Tagalog (Tagalog) |
| TỜ THÔNG TIN CHO NGƯỜI NHẬN VÀ NHỮNG NGƯỜI CHĂM SÓC (November 19, 2021) |
Tiếng Việt (Vietnamese) |